Cargando…

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

BACKGROUND: Approximately 95% of advanced colorectal cancer patients (CRC) have mismatch repair MMR-proficient (MMRp) tumors, which do not respond to PD1 blockade alone. Preclinical studies have shown that combined histone deacetylases (HDAC) and/or DNA methyltransferases (DNMT) inhibition can induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baretti, Marina, Murphy, Adrian G., Zahurak, Marianna, Gianino, Nicole, Parkinson, Rose, Walker, Rosalind, Lopez-Vidal, Tamara Y., Zheng, Lei, Rosner, Gary, Ahuja, Nita, Kurt, Schalper, Azad, Nilofer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149019/ https://www.ncbi.nlm.nih.gov/pubmed/37120591 http://dx.doi.org/10.1186/s13148-023-01485-x

Ejemplares similares

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype
por: Baretti, Marina, et al.
Publicado: (2021)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
por: Domingo-Musibay, Evidio, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
por: Heumann, Thatcher R., et al.
Publicado: (2022)

Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer
por: Baretti, Marina, et al.
Publicado: (2022)

Mutational profiling of colorectal cancers with microsatellite instability
por: Lin, Elaine I., et al.
Publicado: (2015)

3475 A TL1 Team Approach to CNS-Localized Delivery of Neurotrophic Factors for Treatment of Parkinson’s Disease
por: Gopinath, Adithya, et al.
Publicado: (2019)

Effects of the addition of leucine on flavor and quality of sausage fermented by Lactobacillus fermentum YZU-06 and Staphylococcus saprophyticus CGMCC 3475
por: Liu, Rui, et al.
Publicado: (2023)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
por: Senda, Masaya, et al.
Publicado: (2023)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
por: Garralda, E., et al.
Publicado: (2022)

Vitamin D status among patients visiting a tertiary care center in Riyadh, Saudi Arabia: a retrospective review of 3475 cases
por: Alfawaz, Hanan, et al.
Publicado: (2014)

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2017)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
por: Ikeda, Yuki, et al.
Publicado: (2021)

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer
por: Kai, Yugo, et al.
Publicado: (2021)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
por: Viúdez, Antonio, et al.
Publicado: (2016)

Microsatellites grant more stable flanking genes
por: Joukhadar, Reem, et al.
Publicado: (2012)

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab
por: Naganuma, Atsushi, et al.
Publicado: (2020)

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery
por: Woods, Alexander D., et al.
Publicado: (2022)

SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers
por: Chia, June A, et al.
Publicado: (2006)

Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High
por: Kawai, Koji, et al.
Publicado: (2021)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
por: O'Malley, David M., et al.
Publicado: (2022)

The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

EMAST Type of Microsatellite Instability—A Distinct Entity or Blurred Overlap between Stable and MSI Tumors
por: Vuković Đerfi, Kristina, et al.
Publicado: (2023)

The acid–base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury
por: Dharmaraj, Karuppasamy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gh9s06f83cpea20be9aqm94snt